MA35861B1 - Inhibiteur de la kinase régulant les signaux de l'apoptose - Google Patents
Inhibiteur de la kinase régulant les signaux de l'apoptoseInfo
- Publication number
- MA35861B1 MA35861B1 MA37202A MA37202A MA35861B1 MA 35861 B1 MA35861 B1 MA 35861B1 MA 37202 A MA37202 A MA 37202A MA 37202 A MA37202 A MA 37202A MA 35861 B1 MA35861 B1 MA 35861B1
- Authority
- MA
- Morocco
- Prior art keywords
- apoptosis
- signals
- kinase inhibitor
- regulating
- inhibitor regulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (i). Le composé possède une activité inhibitrice de la kinase régulant les signaux de l'apoptose (« ask 1 ») et est donc utile dans le traitement de maladies telles que la néphropathie, la néphropathie diabétique et la fibrose rénale.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591710P | 2012-01-27 | 2012-01-27 | |
PCT/US2013/022997 WO2013112741A1 (fr) | 2012-01-27 | 2013-01-24 | Inhibiteur de la kinase régulant les signaux de l'apoptose |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35861B1 true MA35861B1 (fr) | 2014-12-01 |
Family
ID=47684038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37202A MA35861B1 (fr) | 2012-01-27 | 2014-07-11 | Inhibiteur de la kinase régulant les signaux de l'apoptose |
Country Status (40)
Country | Link |
---|---|
US (7) | US8742126B2 (fr) |
EP (1) | EP2807151B1 (fr) |
JP (1) | JP5770950B2 (fr) |
KR (5) | KR101799739B1 (fr) |
CN (2) | CN104080771B (fr) |
AP (1) | AP2014007836A0 (fr) |
AR (2) | AR089818A1 (fr) |
AU (1) | AU2013201586C1 (fr) |
BR (1) | BR112014018355B1 (fr) |
CA (3) | CA2862030C (fr) |
CL (1) | CL2014001988A1 (fr) |
CO (1) | CO7061073A2 (fr) |
CR (1) | CR20140405A (fr) |
CY (1) | CY1117201T1 (fr) |
DK (1) | DK2807151T3 (fr) |
EA (1) | EA024746B1 (fr) |
ES (1) | ES2558203T3 (fr) |
HK (1) | HK1204324A1 (fr) |
HR (1) | HRP20151399T1 (fr) |
HU (1) | HUE028641T2 (fr) |
IL (3) | IL233598A (fr) |
IN (1) | IN2014DN06174A (fr) |
MA (1) | MA35861B1 (fr) |
MD (1) | MD4601B1 (fr) |
ME (1) | ME02322B (fr) |
MX (3) | MX2014009075A (fr) |
NZ (1) | NZ739339A (fr) |
PE (1) | PE20141822A1 (fr) |
PH (1) | PH12014501697B1 (fr) |
PL (1) | PL2807151T3 (fr) |
PT (1) | PT2807151E (fr) |
RS (1) | RS54492B1 (fr) |
SG (1) | SG11201404348UA (fr) |
SI (1) | SI2807151T1 (fr) |
SM (1) | SMT201600047B (fr) |
TW (4) | TWI561514B (fr) |
UA (1) | UA112098C2 (fr) |
UY (1) | UY34573A (fr) |
WO (1) | WO2013112741A1 (fr) |
ZA (1) | ZA201405260B (fr) |
Families Citing this family (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
EP3074016A2 (fr) | 2013-11-26 | 2016-10-05 | Gilead Sciences, Inc. | Therapies pour le traitement de troubles myeloproliferatifs |
US20160331754A1 (en) | 2014-01-20 | 2016-11-17 | Gilead Sciences, Inc. | Therapies for treating cancers |
US20150342943A1 (en) * | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
TW201618781A (zh) * | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
CA2962572A1 (fr) * | 2014-09-24 | 2016-03-31 | Gilead Sciences, Inc. | Methodes de traitement de maladie du foie a l'aide d'une combinaison d'un inhibiteur de ask1 et d'un agoniste fxr |
MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
CA2972192C (fr) | 2014-12-23 | 2021-07-06 | Gilead Sciences, Inc. | Procedes de preparation d'inhibiteurs de l'ask1 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
PT3321265T (pt) | 2015-03-04 | 2020-07-07 | Gilead Sciences Inc | Compostos 4,6-diamino-pirido[3,2-d]pirimidina compounds e a sua utilização como moduladores de receptores do tipo toll |
CA2971640C (fr) | 2015-07-06 | 2020-09-22 | Gilead Sciences, Inc. | Modulateurs de cot et procedes d'utilisation associes |
WO2017059224A2 (fr) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combinaison d'un inhibiteur de btk et d'un inhibiteur de point de contrôle pour le traitement de cancers |
CA3006772A1 (fr) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Composes inhibiteurs de kinases se liant a tank |
JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ, インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
WO2017177179A1 (fr) | 2016-04-08 | 2017-10-12 | Gilead Sciences, Inc. | Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes |
JP6730466B2 (ja) | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗pd−l1抗体およびその使用 |
MA45848A (fr) | 2016-08-04 | 2019-06-12 | Gilead Sciences Inc | Cobicistat destiné à être utilisé dans des traitements du cancer |
ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
JP6746776B2 (ja) | 2016-09-02 | 2020-08-26 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体調節剤化合物 |
US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
WO2018089212A1 (fr) | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Procédé de traitement d'une maladie hépatique |
US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
WO2018133865A1 (fr) * | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | Inhibiteur de ask1, sa méthode de préparation et son utilisation |
SG11201906579UA (en) * | 2017-01-22 | 2019-08-27 | Fujian Cosunter Pharmaceutical Co Ltd | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
EP4050030A1 (fr) | 2017-01-24 | 2022-08-31 | I-Mab Biopharma US Limited | Anticorps anti-cd73 et leurs utilisations |
WO2018156895A1 (fr) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibiteurs de la tyrosine kinase de bruton |
EP3585789A1 (fr) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibiteurs de tyrosine kinase de bruton |
WO2018157277A1 (fr) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Composés d'isoquinoléine et de naphtydrine |
KR20190126322A (ko) * | 2017-03-03 | 2019-11-11 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 아미드 유도체 억제제 및 그의 제조 방법 및 적용 |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
AU2018246209A1 (en) | 2017-03-28 | 2019-09-19 | Gilead Sciences, Inc. | Methods of treating liver disease |
US20180333401A1 (en) | 2017-04-12 | 2018-11-22 | Gilead Sciences, Inc. | Methods of treating liver disease |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
WO2018209354A1 (fr) | 2017-05-12 | 2018-11-15 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de kinases de régulation du signal d'apoptose 1 et leurs procédés d'utilisation |
WO2018218042A1 (fr) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de kinase de régulation de signal d'apoptose 1 et leurs procédés d'utilisation |
WO2018218051A1 (fr) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de kinase 1 de régulation du signal apoptotique, et leurs méthodes d'utilisation |
WO2018218044A2 (fr) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Inhibiteurs de la kinase 1 de régulation de signal d'apoptose et leurs méthodes d'utilisation |
WO2018231851A1 (fr) | 2017-06-13 | 2018-12-20 | Gilead Sciences, Inc. | Méthodes de traitement de la fibrose hépatique |
WO2019015559A1 (fr) * | 2017-07-18 | 2019-01-24 | 南京圣和药业股份有限公司 | Composé hétérocyclique agissant en tant qu'inhibiteur d'ask et utilisation de celui-ci |
WO2019046186A1 (fr) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal apoptotique contenant des tétrazoles et méthodes d'utilisation de ceux-ci |
CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
US10370352B2 (en) | 2017-09-07 | 2019-08-06 | Eli Lilly And Company | Cyclobutyl-imidazolidinone compounds |
WO2019047094A1 (fr) * | 2017-09-07 | 2019-03-14 | Eli Lilly And Company | Composés de cyclobutyle-imidazolidinone |
WO2019047161A1 (fr) * | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | Composés d'imidazolidine |
JP2020533335A (ja) | 2017-09-08 | 2020-11-19 | フロンセラ ユー.エス. ファーマシューティカルズ エルエルシー | アポトーシスシグナル調節キナーゼ阻害剤およびその使用 |
CN111518080A (zh) * | 2017-10-12 | 2020-08-11 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
WO2019094777A1 (fr) | 2017-11-13 | 2019-05-16 | Gilead Sciences, Inc. | Compositions et méthodes d'identification et de traitement de maladies hépatiques et de surveillance des résultats du traitement |
WO2019123340A1 (fr) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides 3'3' cycliques ayant une liaison phosphonate activant la protéine adaptatrice de sting |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
CA3093888A1 (fr) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucleotides 3'3'-cycliques |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
EP3773577A4 (fr) | 2018-04-12 | 2021-12-01 | Terns, Inc. | Inhibiteurs d'ask1 tricycliques |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CA3097982A1 (fr) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 regulant le signal d'apoptose contenant des tetrazoles et leurs methodes d'utilisation |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
CA3098873A1 (fr) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticules et nanoparticules ayant des charges de surface negatives |
CA3099152C (fr) | 2018-05-14 | 2023-10-24 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 |
WO2020006429A1 (fr) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Inhibiteurs d'isoindolin-1-one ask1 et leurs procédés d'utilisation |
EP4234030A3 (fr) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Inhibiteurs de pd-1/pd-l1 |
WO2020015721A1 (fr) * | 2018-07-20 | 2020-01-23 | 福建广生堂药业股份有限公司 | Forme cristalline utilisée en tant qu'inhibiteur d'ask1, son procédé de préparation et son utilisation |
WO2020041417A1 (fr) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose contenant un cycloalkyle et leurs procédés d'utilisation |
WO2020072656A1 (fr) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Dérivés d'imidozopyrimidine |
KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
LT3873903T (lt) | 2018-10-31 | 2024-05-10 | Gilead Sciences, Inc. | Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai |
CA3116347A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1 |
CN111170995A (zh) * | 2018-11-09 | 2020-05-19 | 山东轩竹医药科技有限公司 | Ask1抑制剂及其应用 |
US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
HRP20240265T1 (hr) | 2019-01-15 | 2024-05-10 | Gilead Sciences, Inc. | Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže |
CN109813915A (zh) * | 2019-02-15 | 2019-05-28 | 浠思(上海)生物技术有限公司 | 利用htrf一步法筛选激酶抑制剂的方法 |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
JP7350872B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3’3’-環状ジヌクレオチドおよびそのプロドラッグ |
WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
EP3937908A1 (fr) | 2019-03-11 | 2022-01-19 | Gilead Sciences, Inc. | Formulations d'un composé et utilisations associées |
WO2020198214A1 (fr) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs procédés d'utilisation |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
WO2020237025A1 (fr) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
US20220332700A1 (en) * | 2019-06-26 | 2022-10-20 | Mankind Pharma Ltd | Novel apoptosis signal-regulating kinase 1 inhibitors |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
JP7431961B2 (ja) | 2019-11-15 | 2024-02-15 | ギリアード サイエンシーズ, インコーポレイテッド | Lpa受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 |
CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
KR20220131918A (ko) | 2019-12-24 | 2022-09-29 | 카나 바이오사이언스, 인코포레이션 | 다이아실글리세롤 키나제 조절 화합물 |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
KR20220161438A (ko) | 2020-03-30 | 2022-12-06 | 길리애드 사이언시즈, 인코포레이티드 | Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태 |
WO2021202688A1 (fr) | 2020-04-02 | 2021-10-07 | Gilead Sciences, Inc. | Procédé de préparation d'un composé inhibiteur de cot |
IL297327A (en) | 2020-05-01 | 2022-12-01 | Gilead Sciences Inc | 4,2-deoxypyrimidine compounds that inhibit cd73 |
KR20230019880A (ko) | 2020-06-03 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
CN114470217B (zh) * | 2020-11-24 | 2023-06-20 | 深圳微芯生物科技股份有限公司 | 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物 |
WO2022192428A1 (fr) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Composés modulateurs de glp-1r |
KR20230158542A (ko) | 2021-03-29 | 2023-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Khk 억제제 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CN114246866B (zh) * | 2021-04-28 | 2023-09-12 | 深圳微芯生物科技股份有限公司 | 用于治疗慢性肾病的药物及其用途 |
TW202400561A (zh) | 2021-05-11 | 2024-01-01 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
JP2024517479A (ja) | 2021-05-13 | 2024-04-22 | ギリアード サイエンシーズ, インコーポレイテッド | Lpa受容体アンタゴニスト及びそれらの使用 |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療fxr誘發之搔癢之il-31調節劑 |
CA3220923A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes de modulation de la diacylglycerol kinase |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
WO2022271684A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (fr) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Dérivés de pyridine-3(2h)-one |
WO2023077030A1 (fr) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Composés cd73 |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Anticorps ciblant 5t4 et leurs utilisations |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
CN115844887B (zh) * | 2022-12-28 | 2023-09-08 | 中国人民解放军空军军医大学 | Selonsertib在制备治疗癌症的药物中的用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998034946A1 (fr) | 1997-02-12 | 1998-08-13 | Massachusetts Institute Of Technology | Daxx, nouvelle proteine fixatrice de fas activant une jnk (kinase n-terminale de jun) et l'apoptose |
SI1144600T1 (sl) | 1999-03-19 | 2008-12-31 | Aventis Pharma Inc | AKT-3-nukleinske kisline, polipeptidi in njihove uporabe |
US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
WO2001095410A1 (fr) * | 2000-06-07 | 2001-12-13 | Andelman Marc D | Cellules, systeme et procede electrochimiques de recyclage a connexion fluidique et electrique |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
EP1661581A1 (fr) | 2003-07-28 | 2006-05-31 | Osaka Industrial Promotion Organization | Traitement de l'insuffisance cardiaque contenant comme principe actif un inhibiteur d'ask1 et procede de criblage de celui-ci |
JP2008514635A (ja) | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
US7696202B2 (en) | 2004-11-10 | 2010-04-13 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
EP1677113A1 (fr) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Procédé d'identification des interactions protéine-protéine dans des réseaux de protéines associés aux maladies |
US20070276050A1 (en) * | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
EP2058309A4 (fr) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | Composé hétérocyclique à cycles fusionnés |
WO2008042867A2 (fr) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulateurs de kinases multiples |
AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
EP1942104A1 (fr) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Hétéroarylcyclopropanecarboxamide et leur utilisation pharmaceutique |
US8104727B2 (en) | 2007-03-12 | 2012-01-31 | Denis Joanisse | Adjustable article support |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2009027283A1 (fr) | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Composés de triazolopyridine et leur utilisation comme inhibiteurs de ask |
JP5432982B2 (ja) | 2008-03-31 | 2014-03-05 | 武田薬品工業株式会社 | アポトーシスシグナル調節キナーゼ1阻害剤 |
WO2010008843A1 (fr) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinases 1 régulant le signal apoptotique |
WO2010045470A2 (fr) | 2008-10-15 | 2010-04-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, et procédés d'identification, d'évaluation, de prévention, et de thérapie de troubles hépatiques |
WO2010056982A2 (fr) | 2008-11-17 | 2010-05-20 | The George Washington University | Compositions et procédés pour identifier des troubles du spectre de l'autisme |
WO2010111464A1 (fr) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibition par interférence arn de l'expression du gène kinase 1 de régulation du signal d'apoptose (ask1) au moyen d'un acide nucléique interférent court (ansi) |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
WO2011041293A1 (fr) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose |
US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
WO2011097594A2 (fr) | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Methodes therapeutiques et compositions impliquant l'inhibition de la kinase allosterique |
AU2011232372B2 (en) | 2010-03-24 | 2016-06-30 | Amitech Therapeutic Solutions, Inc. | Heterocyclic compounds useful for kinase inhibition |
PL2588475T3 (pl) * | 2010-07-02 | 2015-10-30 | Gilead Sciences Inc | Inhibitory kinazy regulującej sygnał apoptozy |
WO2012068464A2 (fr) | 2010-11-18 | 2012-05-24 | University Of Delaware | Procédés de traitement et de prévention de maladies thrombotiques utilisant des inhibiteurs de l'ask1 |
US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
CN103492590A (zh) | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | 循环生物标志物 |
AU2012267884A1 (en) | 2011-06-07 | 2014-01-23 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for cancer |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
US8924765B2 (en) | 2011-07-03 | 2014-12-30 | Ambiq Micro, Inc. | Method and apparatus for low jitter distributed clock calibration |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
CA2972192C (fr) | 2014-12-23 | 2021-07-06 | Gilead Sciences, Inc. | Procedes de preparation d'inhibiteurs de l'ask1 |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
-
2013
- 2013-01-11 UY UY0001034573A patent/UY34573A/es not_active Application Discontinuation
- 2013-01-24 KR KR1020177003620A patent/KR101799739B1/ko active IP Right Grant
- 2013-01-24 US US13/748,901 patent/US8742126B2/en active Active
- 2013-01-24 NZ NZ739339A patent/NZ739339A/en unknown
- 2013-01-24 SG SG11201404348UA patent/SG11201404348UA/en unknown
- 2013-01-24 KR KR1020187037026A patent/KR20190000898A/ko not_active Application Discontinuation
- 2013-01-24 AP AP2014007836A patent/AP2014007836A0/xx unknown
- 2013-01-24 AU AU2013201586A patent/AU2013201586C1/en active Active
- 2013-01-24 CA CA2862030A patent/CA2862030C/fr active Active
- 2013-01-24 UA UAA201407926A patent/UA112098C2/uk unknown
- 2013-01-24 DK DK13703675.2T patent/DK2807151T3/en active
- 2013-01-24 KR KR1020147023533A patent/KR101582065B1/ko active IP Right Grant
- 2013-01-24 PE PE2014001153A patent/PE20141822A1/es active IP Right Grant
- 2013-01-24 PL PL13703675T patent/PL2807151T3/pl unknown
- 2013-01-24 CN CN201380006957.0A patent/CN104080771B/zh active Active
- 2013-01-24 PT PT137036752T patent/PT2807151E/pt unknown
- 2013-01-24 CA CA3026700A patent/CA3026700C/fr active Active
- 2013-01-24 EA EA201491283A patent/EA024746B1/ru unknown
- 2013-01-24 ME MEP-2016-5A patent/ME02322B/me unknown
- 2013-01-24 MD MDA20140082A patent/MD4601B1/ro not_active IP Right Cessation
- 2013-01-24 KR KR1020157036387A patent/KR101707764B1/ko active IP Right Grant
- 2013-01-24 WO PCT/US2013/022997 patent/WO2013112741A1/fr active Application Filing
- 2013-01-24 MX MX2014009075A patent/MX2014009075A/es active IP Right Grant
- 2013-01-24 HU HUE13703675A patent/HUE028641T2/en unknown
- 2013-01-24 BR BR112014018355-4A patent/BR112014018355B1/pt active IP Right Grant
- 2013-01-24 RS RS20160019A patent/RS54492B1/en unknown
- 2013-01-24 SI SI201330109A patent/SI2807151T1/sl unknown
- 2013-01-24 MX MX2015009422A patent/MX365954B/es unknown
- 2013-01-24 CA CA3026738A patent/CA3026738C/fr active Active
- 2013-01-24 ES ES13703675.2T patent/ES2558203T3/es active Active
- 2013-01-24 EP EP13703675.2A patent/EP2807151B1/fr active Active
- 2013-01-24 KR KR1020177032774A patent/KR20170128622A/ko not_active Application Discontinuation
- 2013-01-24 CN CN201811215092.XA patent/CN109438418B/zh active Active
- 2013-01-24 JP JP2014554828A patent/JP5770950B2/ja active Active
- 2013-01-25 TW TW103125752A patent/TWI561514B/zh active
- 2013-01-25 AR ARP130100241A patent/AR089818A1/es active IP Right Grant
- 2013-01-25 TW TW105128669A patent/TWI634890B/zh active
- 2013-01-25 TW TW102102991A patent/TWI487523B/zh active
- 2013-01-25 TW TW107127139A patent/TW201916877A/zh unknown
-
2014
- 2014-04-16 US US14/254,342 patent/US9254284B2/en active Active
- 2014-04-16 US US14/254,359 patent/US9333197B2/en active Active
- 2014-07-10 IL IL233598A patent/IL233598A/en active IP Right Grant
- 2014-07-11 MA MA37202A patent/MA35861B1/fr unknown
- 2014-07-17 ZA ZA2014/05260A patent/ZA201405260B/en unknown
- 2014-07-22 IN IN6174DEN2014 patent/IN2014DN06174A/en unknown
- 2014-07-25 MX MX2019007348A patent/MX2019007348A/es unknown
- 2014-07-25 CL CL2014001988A patent/CL2014001988A1/es unknown
- 2014-07-25 PH PH12014501697A patent/PH12014501697B1/en unknown
- 2014-08-26 CO CO14186994A patent/CO7061073A2/es unknown
- 2014-08-29 CR CR20140405A patent/CR20140405A/es unknown
-
2015
- 2015-05-21 HK HK15104864.8A patent/HK1204324A1/zh unknown
- 2015-06-10 IL IL239311A patent/IL239311B/en active IP Right Grant
- 2015-12-22 HR HRP20151399TT patent/HRP20151399T1/hr unknown
-
2016
- 2016-02-15 SM SM201600047T patent/SMT201600047B/it unknown
- 2016-02-16 CY CY20161100129T patent/CY1117201T1/el unknown
- 2016-04-27 US US15/140,204 patent/US9750730B2/en active Active
-
2017
- 2017-04-19 US US15/491,689 patent/US9873682B2/en active Active
- 2017-12-13 US US15/840,429 patent/US20180099950A1/en not_active Abandoned
-
2018
- 2018-03-07 IL IL257965A patent/IL257965A/en unknown
-
2019
- 2019-01-11 US US16/246,199 patent/US10508100B2/en active Active
- 2019-11-19 AR ARP190103385A patent/AR117113A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35861B1 (fr) | Inhibiteur de la kinase régulant les signaux de l'apoptose | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MA46337A (fr) | Composé de pyridine | |
MA35623B1 (fr) | Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives | |
EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
NZ628028A (en) | Processes for the preparation of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine | |
EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
EA201200373A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
EA201500278A1 (ru) | Пиразолилхиназолиновые ингибиторы киназы | |
EA201790660A1 (ru) | Ингибитор киназ | |
SG178591A1 (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
EA201290910A1 (ru) | Соединения 7-(1н-пиразол-4-ил)-1,6-нафтиридина в качестве ингибиторов syk | |
EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
TN2011000654A1 (fr) | Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant | |
MX366839B (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4. | |
MX2017000522A (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde. | |
PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
UA115052C2 (uk) | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор | |
EA201591369A1 (ru) | Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10) | |
EA201171030A1 (ru) | 2-МОРФОЛИНОПИРИДО[3,2-d]ПИРИМИДИНЫ | |
MA38491A1 (fr) | Dérivé dihydropyridazine-3,5-dione |